Advanced search
Publication Cover
Nanomedicine Volume 8, 2013 - Issue 3
Submit an article Journal homepage
178
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Assessing The Need for Quality-Adjusted Cost–Effectiveness Studies of Nanotechnological Cancer Therapies

Rita Bosetti1 Hasselt University, Department of Applied Economics, Martelarenlaan 42, BE3500 Hasselt, BelgiumCorrespondence[email protected]
View further author information
,
Wim Marneffe1 Hasselt University, Department of Applied Economics, Martelarenlaan 42, BE3500 Hasselt, BelgiumView further author information
&
Lode Vereeck1 Hasselt University, Department of Applied Economics, Martelarenlaan 42, BE3500 Hasselt, BelgiumView further author information
Pages 487-497 | Published online: 11 Mar 2013

References

  • Sarin R . Criteria for deciding cost–effectiveness for expensive new anti-cancer agents. J. Cancer Res. Ther.4(1), 1–2 (2008).
  • Hullmann A . Who is winning the global nanorace? Nat. Nanotechnol.1, 81–83 (2006).
  • Bosetti R , VereeckL. The future of nanomedicines: obstacles and remedies. Nanomedicine6(4), 747–755 (2011).
  • Chan VSW . Nanomedicine: an unresolved regulatory issue. Regul. Toxicol. Pharm.46(3), 218–224 (2006).
  • Orive G , HernandezRM, GasconARet al. Micro and nano drug delivery systems in cancer therapy. Cancer Ther. 3, 131–138 (2005).
  • Bawa R . Patents and nanomedicines. Nanomedicine2(3), 351–374 (2007).
  • Bosetti R , VereeckL. The impact of effective patents on future innovations in nanomedicines. Pharm. Pat. Analyst1(1), 37–43 (2012).
  • Barenholz YC . Doxil – the first FDA-approved nano-drug: lessons learned. J. Control. Release160, 117–134 (2012).
  • Orszag PR , EllisP. Addressing rising health care costs – a view from the Congressional Budget Office. N. Engl. J. Med.357, 1885–1887 (2007).
  • Gafni A , BirchS. Incremental cost–effectiveness ratios (ICERs): the silence of the lambda. Soc. Sci. Med.62(9), 2091–2100 (2006).
  • Smith DH , AdamsJR, JohnstonSRD, GordonA, DrummondMF, BennettC. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann. Oncol.13(10), 1590–1597 (2002).
  • Cagnoni PJ , WalshTJ, PrendergastMM. Pharmacoeconomic analysis of liposomal amphotericin B versus convention amphotericin B in the empirical treatment of persistently febrile neutropenic patients with systemic fungal infections. J. Clin. Oncol.18(12), 2476–2483 (2000).
  • Capri S , CattaneoG. Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. Clin. Ther.25(6), 1826–1845 (2003).
  • Forbes C , WilbyJ, RichardsonG, SculpherM, MatherL, RiemsmaR. A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer. Health Technol. Assess.6(23), 1–119 (2002).
  • Gradishar W , WolinskyS, VishalpuraT, NightengaleB, BramleyT. Cost–effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC). J. Clin. Oncol.22(14), 635–639 (2004).
  • Hjortsberg C , PerssonU, LidbrinkE, BennetC. Cost–effectiveness analysis of pegylated liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi‘s Sarcoma. Acta Oncol.38(8), 1063–1067 (1999).
  • Limat S , DemesmeyK, FagnoniPet al. Cost–effectiveness of cardioprotective strategies in patients with aggressive non-Hodgkin‘s lymphoma. Clin. Drug Invest. 25(11), 719–729 (2005).
  • Main C , BojkeL, GriffinSet al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol. Assess. 10(9), 1–132 (2006).
  • Ojeda B , de Sande LM, Casado A, Merino P, Casado MA. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Brit. J. Cancer89(6), 1002–1007 (2003).
  • Gordon AN , FleagleJT, GuthrieD, ParkinDE, GoreME, LacaveAJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19(14), 3312–3322 (2001).
  • Weintraub WS , CohenDJ. The limits of cost–effectiveness analysis. Circulation2, 55–58 (2009).
  • Vanni T , FonsecaBAL, PolanczykCA. Cost–effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi‘s sarcoma in Brazil. HIV Clin. Trials7(4), 194–202 (2006).
  • Porter CA , RifkinRM. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Clin. Lymphoma Myeloma7(4), 150–155 (2007).
  • Fountzilas G , PapakostasP, DafniUet al. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 17, 1560–1567 (2006).
  • Stinchcombe TE . Nanoparticle albumin-bound paclitaxel: a novel cremophor-EL-free formulation of paclitaxel. Nanomedicine2(4), 415–423 (2007).
  • Dranitsaris G , CottrellW, SpirovskiB, HopkinsS. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J. Oncol. Pharm. Pract.15(2), 67–78 (2008).
  • Ioannis SV . Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine7, 11–17 (2011).
  • Chalkidou K , RawlinsM. Pharmacogenetics and cost–effectiveness analysis: a two-way street. Drug Discov. Today16(19), 873–877 (2011).
  • Cohen JP . Overcoming regulatory and economic challenges facing pharmacogenomics. N. Biotechnol.29(6), 751–756 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.